NCT07452562Recruiting
Hesperidin RCT in MS
A Randomized, Placebo-Controlled Trial of Hesperidin for Fatigue,Mood, and Cognitive Function in Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 5 Mar 2026
Brief summary (registry, in English)
This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress. Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 28 Feb 2026
- Start date
- 7 Jan 2026
- Primary completion date
- 18 Jan 2027
- Lead sponsor
- Swansea University
- Diseases
- Multiple sclerosis
- NCT number
- NCT07452562
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 7 Jan 2026 to the primary completion date, 18 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Known food allergies, intolerances, or significant gastrointestinal (GI) problems, Participants under the age of 18 years.
Who the study is looking for
- Diagnosis of Multiple Sclerosis, Aged 18 years or older.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| FHMLS, Nutrition Lab Coordinator of this site? Confirm its status | Swansea | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.